This "Orphan Drug" Biotech Could Double in Less Than Three Years

The three biggest Big Pharma "blockbuster" medicines of all time target high cholesterol (Lipitor), inflammatory diseases (Humira), and digestive afflictions (Nexium) and have pulled in a combined $350 billion - and counting. But what about people suffering from rare diseases like cystic fibrosis, pancreatic cancer, and so on? Here in America, Washington understands the need for these "orphan drugs" targeting rare diseases, which is why the "Orphan Drug Act of 1983" offers a seven-year window of tax reductions and the exclusive right to market a drug for a particular rare disease. To date, more than 600 orphan drugs have been approved by the FDA. And the global market for orphan drugs targeting rare diseases is growing at double the rate of the non-orphan market. But more needs to be done. And that "more" will create a massive investment portal - provided you pick the best-positioned companies. The post This "Orphan Drug" Biotech Could Double in Less Than Three Years appeared first on Money Morning - We Make Investing Profitable . That's why today, our Michael Robinson going to show you a revved-up leader in the specialty-drugs market whose shares could double in under three years... Tags: biotechnology To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2020 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.